ArticlePloS one2014
Inhibitory activity of the isoflavone biochanin A on intracellular bacteria of genus Chlamydia and initial development of a buccal formulation.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 63 citations in OpenAlex.
- Biochanin A, a Plant Isoflavone, Disrupts Peptidoglycan Biosynthesis by DownregulatingAntibiotics (Basel, Switzerland) · 2026Article
- A multi-strategy antimicrobial discovery approach reveals new ways to treat Chlamydia.PLoS biology · 2025Article
- Plant-Derived Antimicrobials and Their Crucial Role in Combating Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2024Review
- Biochanin A inhibits endothelial dysfunction induced by IL‑6‑stimulated endothelial microparticles in Perthes disease via the NFκB pathway.Experimental and therapeutic medicine · 2024Article
- Biochanin A Inhibits the Growth and Biofilm ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Prediction of the active compounds and mechanism of Biochanin A in the treatment of Legg-Calvé-Perthes disease based on network pharmacology and molecular docking.BMC complementary medicine and therapies · 2024Article
- Neuroprotective potential of biochanin-A and review of the molecular mechanisms involved.Molecular biology reports · 2023Review
- Chemical and Biological Properties of Biochanin A and Its Pharmaceutical Applications.Pharmaceutics · 2023Review
- Mechanisms Behind the Pharmacological Application of Biochanin-A: A review.F1000Research · 2023Review
- Rare prenylated isoflavonoids from the young twigs ofRSC advances · 2022Article
- Escaping mechanisms of ESKAPE pathogens from antibiotics and their targeting by natural compounds.Biotechnology reports (Amsterdam, Netherlands) · 2022Article
- Electrospun Poly(lactide) Fibers as Carriers for Controlled Release of Biochanin A.Pharmaceutics · 2022Article
- Modified Biochanin A Release from Dual pH- and Thermo-Responsive Copolymer Hydrogels.Polymers · 2021Article
- Supercritical Extraction of Red Propolis: Operational Conditions and Chemical Characterization.Molecules (Basel, Switzerland) · 2020Article
- Review on plant antimicrobials: a mechanistic viewpoint.Antimicrobial resistance and infection control · 2019Review
- Perspectives Regarding the Role of Biochanin A in Humans.Frontiers in pharmacology · 2019Review
- Red FluorescentFrontiers in microbiology · 2018Article
- The Benzopyrone Biochanin-A as a reversible, competitive, and selective monoamine oxidase B inhibitor.BMC complementary and alternative medicine · 2017Article
- Lead Discovery Strategies for Identification of Chlamydia pneumoniae Inhibitors.Microorganisms · 2016Review
- Natural Products for the Treatment of Chlamydiaceae Infections.Microorganisms · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the established role of Chlamydia spp. as causative agents of both acute and chronic diseases, search for new antimicrobial agents against these intracellular bacteria is required to promote human health. Isoflavones are naturally occurring phytoestrogens, antioxidants and efflux pump inhibitors, but their therapeutic use is limited by poor water-solubility and intense first-pass metabolism. Here, we report on effects of isoflavones against C. pneumoniae and C. trachomatis and describe buccal permeability and initial formulation development for biochanin A. Biochanin A was the most potent Chlamydia growth inhibitor among the studied isoflavones, with an IC50 = 12 µM on C. pneumoniae inclusion counts and 6.5 µM on infectious progeny production, both determined by immunofluorescent staining of infected epithelial cell cultures. Encouraged by the permeation of biochanin A across porcine buccal mucosa without detectable metabolism, oromucosal film formulations were designed and prepared by a solvent casting method. The film formulations showed improved dissolution rate of biochanin A compared to powder or a physical mixture, presumably due to the solubilizing effect of hydrophilic additives and presence of biochanin A in amorphous state. In summary, biochanin A is a potent inhibitor of Chlamydia spp., and the in vitro dissolution results support the use of a buccal formulation to potentially improve its bioavailability in antichlamydial or other pharmaceutical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.